Výsledky vyhledávání - "Elaine Tat Lam"

Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001)

Autor: James Brugarolas, Katy Beckermann, Brian I. Rini, Nicholas J. Vogelzang, Elaine Tat Lam, James C Hamilton, Thomas Schluep, Min Yi, So Wong, Erick Gamelin, Nizar M. Tannir

Publikováno v: Journal of Clinical Oncology. 40:339-339

339 Background: Hypoxia inducible factor-2 alpha (HIF2a) is a transcription factor and key tumorigenic driver of clear cell renal cell carcinoma (ccRCC). Normally, HIF2a is expressed at low levels and targeted for degradation by the von Hippel-Lindau

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4602efa4e3bd32e6f5edf7b7c56747c5
https://doi.org/10.1200/jco.2022.40.6_suppl.339

Zobrazit plný text záznamu

Impact of neoadjuvant immune checkpoint inhibitor therapy on primary tumor size and complexity: Correlation with surgical quality and short term oncological outcomes

Publikováno v: Journal of Clinical Oncology. 40:390-390

390 Background:The concept of primary systemic therapy has gained increasing traction in the management of metastatic and locally advanced Renal Cell Carcinoma (RCC). Most series have evaluated the use of tyrosine-kinase inhibitors, however, with the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7ec2fba6a469b076eb5884a9c36c2c06
https://doi.org/10.1200/jco.2022.40.6_suppl.390

Zobrazit plný text záznamu

Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients

Autor: Mario E. Lacouture, Anisha B Patel, Nicole R. LeBoeuf, Omkar Subhash Marathe, Jonathan Leventhal, Jennifer N. Choi, Elaine Tat Lam, Benjamin S. Kaffenberger, Martin H Voss, Mark L Webb, Robert Claude Tyler, Juegang Ju, Hong Tang, Jie Luo, Milan J. Anadkat, Nicholas J. Vogelzang

Publikováno v: Journal of Clinical Oncology. 40:TPS396-TPS396

TPS396 Background: Hand-foot skin reaction (HFSR) is associated with the use of multi-targeted tyrosine kinase inhibitors sharing vascular endothelial growth factor receptor inhibitory (VEGFRi) activity (e.g., cabozantinib, regorafenib, sorafenib, su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86e2ecd38aa3a5b45da251c80d4821ff
https://doi.org/10.1200/jco.2022.40.6_suppl.tps396

Zobrazit plný text záznamu

SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer

Autor: Evan Y. Yu, Catherine M. Tangen, Celestia S. Higano, Neeraj Agarwal, Sumanta Kumar Pal, Ajjai Shivaram Alva, Elisabeth I. Heath, Elaine Tat Lam, Shilpa Gupta, Michael B. Lilly, Yoshio Inoue, Kim N. Chi, Nicholas J. Vogelzang, David I. Quinn, Hongli Li, Heather H. Cheng, Stephen R Plymate, Maha Hussain, Ian Murchie Thompson

Publikováno v: Journal of Clinical Oncology. 32:5006-5006

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::283916f20bfbafd62d7bf35a0848055a
https://doi.org/10.1200/jco.2014.32.15_suppl.5006

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání